Griguolo et al. have also confirmed that TNBC BMs showed a significantly higher percentage of intra-tumoral CD8+ cells and a higher density of CD163+ M2-polarized microglia/macrophages within the HER2-negative BC BMs, associating the latter with a worse prognosis, but identifying another potential therapeutic target to be explored [46]. The gene discussed is CD8A; the disease is breast cancer.